We are a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. We use our proprietary technology, Cell Squeeze, to physically squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. This technology allows us to create a broad pipeline of product candidates for different diseases. Our goal is to use the SQZ approach to establish a new paradigm for cell therapies.
Our lead product candidate, SQZ-PBMC-HPV, from our SQZ APC platform, is a targeted cancer vaccine that has been designed to generate antigen-specific CD8+ T cell (CD8, CD8 T cell) responses to attack HPV+ tumors. We believe there remains significant unmet need in HPV+ cancers, with over 630,000 new cases every year globally. We are evaluating SQZ-PBMC-HPV in a Phase 1 clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar and vaginal cancer.
|Industry:||BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)|
|Address||200 Arsenal Yards Blvd, Suite 210 Watertown, MA 02472|
|Phone Number||(617) 758-8672|
|View Prospectus:||SQZ Biotechnologies|
|Revenues||$22.82 mil (last 12 months)|
|Net Income||$-38.71 mil (last 12 months)|
|Price range||$16.00 - $16.00|
|Est. $ Volume||$70.6 mil|
|Manager / Joint Managers||BofA Securities/ Evercore/ Stifel|
|Expected To Trade:||10/30/2020|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|